| abstract |
We have discovered that functional antibodies that individually correspond to mutations in the causative gene of the disease can be produced using antibody engineering technology to enable treatment for the disease. Specifically, it has an agonist activity for a receptor (eg, a mutated thrombopoietin receptor whose thrombopoietin (TPO) reactivity has been significantly reduced) whose reactivity to natural ligands has been almost lost due to gene mutation. By allowing the ligand to act, a ligand having an action capable of transmitting a signal close to a normal level, in particular, a low molecular weight antibody was successfully produced. |